[Skip to Content]
[Skip to Content Landing]
Other Articles
November 11, 1950


The Executive Committee The American Venereal Disease Association
Author Affiliations

750 Harrison Avenue, Boston 18.

JAMA. 1950;144(11):947-948. doi:10.1001/jama.1950.02920110059026

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


To the Editor:—  The Officers and Executive Committee of the American Venereal Disease Association occasionally have requests from physicians both here and abroad as to the present status of penicillin in the treatment of syphilis and as to the relative merits of penicillin and arsenic-bismuth compounds in such treatment. One such request came from the Venereal Disease Section of the World Health Organization. The following paragraphs constitute the response to this request. It has the endorsement of the Executive Committee of this Association, and it is hoped that it will clarify the situation as of this date.Before the release of penicillin for the treatment of syphilis in the United States, it was extensively investigated in nationwide studies organized by the Committee of Medicine of the Office of Scientific Research and Development. These studies comprised (a) the treatment with penicillin by various time-dose schedules of patients with early syphilis (more

First Page Preview View Large
First page PDF preview
First page PDF preview